907 related articles for article (PubMed ID: 26752337)
41. Effect of Gastric Acid Suppressants on Response to a Physical Activity Intervention and Major Mobility Disability in Older Adults: Results from the Lifestyle Interventions for Elders (LIFE) Study.
Squires PJ; Pahor M; Manini TM; Brown JD
Pharmacotherapy; 2019 Aug; 39(8):816-826. PubMed ID: 31230397
[TBL] [Abstract][Full Text] [Related]
42. Cumulative Use of Proton Pump Inhibitors and Risk of Dementia: The Atherosclerosis Risk in Communities Study.
Northuis CA; Bell EJ; Lutsey PL; George KM; Gottesman RF; Mosley TH; Whitsel EA; Lakshminarayan K
Neurology; 2023 Oct; 101(18):e1771-e1778. PubMed ID: 37558503
[TBL] [Abstract][Full Text] [Related]
43. Histamine H2-Blocker and Proton Pump Inhibitor Use and the Risk of Pneumonia in Acute Stroke: A Retrospective Analysis on Susceptible Patients.
Arai N; Nakamizo T; Ihara H; Koide T; Nakamura A; Tabuse M; Miyazaki H
PLoS One; 2017; 12(1):e0169300. PubMed ID: 28085910
[TBL] [Abstract][Full Text] [Related]
44. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.
Lazarus B; Wu A; Shin JI; Sang Y; Alexander GC; Secora A; Inker LA; Coresh J; Chang AR; Grams ME
JAMA Intern Med; 2018 Jul; 178(7):903-910. PubMed ID: 29868840
[TBL] [Abstract][Full Text] [Related]
45. Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease.
Hughes J; Y Y Chiu D; Kalra PA; Green D
PLoS One; 2018; 13(5):e0197400. PubMed ID: 29799851
[TBL] [Abstract][Full Text] [Related]
46. The Uncertainty of the Association Between Proton Pump Inhibitor Use and the Risk of Dementia: Prescription Sequence Symmetry Analysis Using a Korean Healthcare Database Between 2002 and 2013.
Park SK; Baek YH; Pratt N; Kalisch Ellett L; Shin JY
Drug Saf; 2018 Jun; 41(6):615-624. PubMed ID: 29397553
[TBL] [Abstract][Full Text] [Related]
47. Long-Term Proton Pump Inhibitor Therapy Increases the Risk of Infection in Patients with Incident Hemodialysis.
Saka Y; Naruse T; Chikamatsu T; Mitani K; Hayashi M; Matsumoto J; Yosizawa Y; Mimura T; Takahashi H; Watanabe Y
Nephron; 2023; 147(10):608-615. PubMed ID: 37231855
[TBL] [Abstract][Full Text] [Related]
48. Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients.
Yang H; Juang SY; Liao KF
Diabetes Res Clin Pract; 2019 Jan; 147():67-75. PubMed ID: 30500543
[TBL] [Abstract][Full Text] [Related]
49. PPIs and kidney disease: from AIN to CKD.
Moledina DG; Perazella MA
J Nephrol; 2016 Oct; 29(5):611-6. PubMed ID: 27072818
[TBL] [Abstract][Full Text] [Related]
50. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs.
Eurich DT; Sadowski CA; Simpson SH; Marrie TJ; Majumdar SR
Am J Med; 2010 Jan; 123(1):47-53. PubMed ID: 20102991
[TBL] [Abstract][Full Text] [Related]
51. Proton Pump Inhibitors, But Not H2-receptor Antagonists, Are Associated With Incident Fractures Among Kidney Transplant Recipients.
Lyu B; Jorgenson MR; Hansen KE; Djamali A; Astor BC
Transplantation; 2020 Dec; 104(12):2609-2615. PubMed ID: 32058466
[TBL] [Abstract][Full Text] [Related]
52. Lack of Association Between Proton Pump Inhibitor Use and Cognitive Decline.
Wod M; Hallas J; Andersen K; García Rodríguez LA; Christensen K; Gaist D
Clin Gastroenterol Hepatol; 2018 May; 16(5):681-689. PubMed ID: 29391266
[TBL] [Abstract][Full Text] [Related]
53. Beyond uncertainty: Negative findings for the association between the use of proton pump inhibitors and risk of dementia.
Park SK; Nam JH; Lee H; Chung H; Lee EK; Shin JY
J Gastroenterol Hepatol; 2019 Dec; 34(12):2135-2143. PubMed ID: 31145825
[TBL] [Abstract][Full Text] [Related]
54. Proton pump inhibitors and chronic kidney disease: is it time to sound the alarm?
Wyatt CM
Kidney Int; 2016 Apr; 89(4):732-3. PubMed ID: 26994567
[TBL] [Abstract][Full Text] [Related]
55. Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists.
Patel KS; Stephany BR; Barnes JF; Bauer SR; Spinner ML
Pharmacotherapy; 2017 Dec; 37(12):1507-1515. PubMed ID: 28976570
[TBL] [Abstract][Full Text] [Related]
56. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
[TBL] [Abstract][Full Text] [Related]
57. Association of Time-Varying Blood Pressure With Chronic Kidney Disease Progression in Children.
Reynolds BC; Roem JL; Ng DKS; Matsuda-Abedini M; Flynn JT; Furth SL; Warady BA; Parekh RS
JAMA Netw Open; 2020 Feb; 3(2):e1921213. PubMed ID: 32058554
[TBL] [Abstract][Full Text] [Related]
58. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
59. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis.
Kwok CS; Arthur AK; Anibueze CI; Singh S; Cavallazzi R; Loke YK
Am J Gastroenterol; 2012 Jul; 107(7):1011-9. PubMed ID: 22525304
[TBL] [Abstract][Full Text] [Related]
60. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.
Ray WA; Murray KT; Griffin MR; Chung CP; Smalley WE; Hall K; Daugherty JR; Kaltenbach LA; Stein CM
Ann Intern Med; 2010 Mar; 152(6):337-45. PubMed ID: 20231564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
